
Niacinamide: Supports barrier function, uneven tone and oiliness. Tranexamic Acid: Topical formulas are studied for melasma, with mixed results.


Choose for barrier support, uneven tone and oiliness; often the gentler starting point.
Consider a topical pigment option; the evidence is mixed and formula-specific.
Can you use both?
A popular gentle pairing for dark spots and melasma.
Compare uses by strength of evidence. Evidence level describes confidence in a benefit, not its size.
















Supports the skin barrier: Helps skin make lipids that reduce water loss. Reduces pigment transfer: Less pigment reaches neighboring skin cells.
Schematic illustration; not a measurement of skin penetration. Effects vary with ingredient identity and formulation.

Affects plasmin-related signaling: May reduce signals that stimulate pigment production. May help uneven pigmentation: Delivery and the formula influence topical results.
Schematic illustration; not a measurement of skin penetration. Effects vary with ingredient identity and formulation.
Built from where each one usually sits in a routine. Introduce one at a time.
Clinical studies commonly use 2–5% niacinamide for particular concerns. Higher marketed strengths are not a proven upgrade for everyone.
2%
4–5%
10%
Studied for facial oiliness
Controlled studies tested a finished formula for measures of facial oiliness; results do not mean every oily skin needs niacinamide.
Studied for tone and skin aging
Different trials studied pigmentation, melasma or fine lines. The concern and finished formula matter.
Higher marketed concentration
Available in skincare, but not established as universally more effective than the lower studied strengths.
Choosing a strength: A comfortable 2–5% product is a reasonable place to look when choosing for the studied concerns; evaluate the complete formula.
Higher strengths: Higher percentages may sting or irritate some skin. Do not keep increasing the concentration when the product causes discomfort.
Formula matters: Niacinamide is also included in moisturizers without a stated percentage. That does not mean the moisturizer cannot support skin comfort.
Topical tranexamic acid studies have used different delivery systems, including 1.8% liposomal lotion and 5% creams or solutions. Oral treatment and procedure-assisted delivery are separate medical decisions.
1.8%
5%
Studied liposomal lotion
One melasma trial tested this delivery system. Its percentage cannot be directly compared with an ordinary serum.
Studied topical formulas
Several melasma studies used topical formulas at this strength. Evidence does not establish one best concentration for all pigment concerns.
Choosing a strength: Look for evidence on the finished topical product. Do not use injectable or oral products as DIY skincare.
Higher strengths: A stronger topical percentage has not been shown to guarantee better results. Oral use requires separate evaluation of risks, including clotting risk.
Formula matters: Liposomal delivery, other brightening ingredients and procedures can change the treatment. A microneedling study is not evidence for the same result from a home serum.
Approximate windows, not promises.
First few weeksAssess comfort. Moisturizer benefits may appear before changes in tone or lines.
First few weeksAssess tolerance first; pigment change is usually slower.
4–8 weeksOiliness or uneven pigmentation may begin to improve.
4–8 weeksSome studied regimens begin showing pigment improvement.
8–12 weeksReassess tone and fine lines; expect modest changes.
8–12 weeksA useful review point for benefit and irritation.
3–6 monthsContinue if it helps and remains comfortable.
3–6 monthsMany melasma trials assess results over three to four months; recurrence is common.
6–12 monthsLong-term benefit is less well defined than short-term results.
6–12 monthsLong-term use depends on the active; follow a monitored plan rather than extending treatment automatically.
Stinging, redness, dryness or a rash can occur. Fragrance, preservatives and other ingredients may also contribute to a reaction.
Can sting or cause redness; do not substitute tablets or injections for a cosmetic product.
Stop for persistent burning, swelling or an itchy rash. Seek urgent help for trouble breathing or rapidly worsening facial swelling.
Stop for persistent burning, swelling, blistering or a new rash. Seek urgent care for breathing difficulty or a severe allergic reaction.
Choose a gentle formula and test a small area. Barrier-support claims do not mean every product suits rosacea or eczema.
Choose a simple formula and test a small area first. Avoid actively inflamed or broken skin unless the product is specifically directed for it.
This topical ingredient is not a retinoid. Review the complete product with your clinician; do not assume every combination formula is suitable.
Niacinamide supports skincare; it does not replace diagnosis or established treatment of persistent acne, melasma or an inflamed rash.
Do not use a cosmetic product as a substitute for diagnosis of an unexplained, changing or persistent skin problem.
Melasma is common in pregnancy, so this comes up constantly. Oral tranexamic acid is not a casual pregnancy decision, and the topical version has little pregnancy-specific data. Ask the doctor managing your pregnancy, since they know your full picture.
On the skin. A water-soluble vitamin used in serums and moisturizers.
Entering skin. Human studies show delivery into the outer skin; uptake depends on the formula.
Conversion. Cells use niacinamide to help make NAD+, which supports energy and repair.
Skin response. Supports production of barrier lipids, including ceramides, and helps reduce water loss.
Additional effects. Reduces pigment transfer between skin cells in laboratory models.
On the skin. The finished product delivers tranexamic acid in a particular vehicle.
Entering skin. Below the 500 Da guideline; delivery still depends on the formula, solubility, stability and skin condition. Size does not prove effectiveness or penetration depth.
Conversion. No activation step is established as necessary for its intended topical role.
Skin response. May affect plasmin-related signalling involved in pigmentation; a small molecular size does not guarantee delivery.
Additional effects. Proposed pathways do not establish a measured depth of delivery or clinical benefit beyond the studies cited.
There is clinical evidence, including a small 12-week controlled trial of a 5% moisturizer. Expect modest improvement; it does not erase deep wrinkles.
Not necessarily. Many clinical studies used 2–5%, and a higher concentration is not proven to work better for every concern.
Small trials suggest benefit, but the evidence is limited. Persistent, painful or scarring acne needs an established acne treatment plan.
That has not been established. Less oil or a smoother appearance can make pores look less obvious without permanently changing their structure.
The concentration, other ingredients or your skin barrier may be responsible. Reduce use or stop if irritation persists; you do not need to push through it.
Consider a topical pigment option; the evidence is mixed and formula-specific.
A small vehicle-controlled 5% trial did not show superiority over vehicle. A larger active-comparator study found improvement in both groups but did not prove equivalence to hydroquinone.
Sources